CClinicalTrials.gg
RecruitingNCT07069517Updated Dec 3, 2025

Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD

An interventional study of Cognitive-Behavioral Therapy for Insomnia (CBTi) and Cognitive Behavioral Therapy for Nightmares (CBTn) in Insomnia, PTSD - Post Traumatic Stress Disorder and Nightmares, sponsored by Palo Alto Veterans Institute for Research. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Palo Alto Veterans Institute for Research · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a two-arm individually randomized group treatment clinical trial evaluating behavioral therapies for insomnia, nightmares, and PTSD. The study will compare cognitive-behavioral therapy for insomnia and nightmares to sleep hygiene (Control), both integrated with Written Exposure Therapy for PTSD and delivered in an accelerated (i.e., 5-day) group treatment format, preceded and followed by individual treatment sessions. 160 participants will be randomized into one of two study conditions.

Read the detailed description

The aims of the study are:

  1. Determine the efficacy of accelerated cognitive behavioral therapy for insomnia and nightmares (CBTi+n) integrated with Written Exposure Therapy (WET) for PTSD for improving insomnia symptoms among military personnel with clinically significant symptoms of insomnia, nightmares, and PTSD.
  2. Determine the efficacy of accelerated CBTi+n integrated with WET for improving nightmare symptoms among military personnel with clinically significant symptoms of insomnia, nightmares, and PTSD.

Exploratory Aim: Determine the efficacy of accelerated CBTi+n integrated with WET for improving PTSD symptoms among military personnel with clinically significant symptoms of insomnia, nightmares, and PTSD.

02

Conditions studied

  • Insomnia
  • PTSD - Post Traumatic Stress Disorder
  • Nightmares
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Defense Enrollment Eligibility Reporting System (DEERS) eligible active-duty military personnel or veteran, 18-65 years old.
  2. Ability to speak and read English.
  3. Clinically significant PTSD symptoms (CAPS-5 > 25 with at least one Intrusion symptom and at least one Avoidance symptom).
  4. Clinically significant symptoms of insomnia disorder (Structured Clinical Interview for Sleep Disturbance DSM-5 (SCISD) Insomnia Criteria are met and Insomnia Severity Index (ISI) > 11).
  5. Nightmares > 1 monthly (as reported on the SCISD).
  6. Willing to refrain from new behavioral health or medication treatment for issues pertaining to PTSD, sleep, and nightmares during study participation.

Exclusion criteria

Exclusion Criteria:

  1. Current suicide or homicide risk meriting crisis intervention.
  2. Inability to comprehend the baseline screening questionnaires.
  3. Unwilling to remain abstinent from alcohol during therapy sessions.
  4. Serious mental health symptoms, such as mania, psychosis, alcohol or substance use disorders warranting immediate clinical attention based on interviewer assessment and clinical judgement.
  5. Currently engaged in evidence-based psychotherapy for PTSD (e.g., Prolonged Exposure Therapy, Cognitive Processing Therapy, Written Exposure Therapy) or insomnia or nightmares (e.g., Cognitive Behavioral Therapy for Insomnia or Nightmares).
  6. Pregnancy, as determined by self-report, because pregnancy can adversely affect sleep outside of PTSD, insomnia, and nightmares.
  7. Working duty shifts ending later than 21:00 or starting before 05:30 more than 2 times per month.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Written exposure therapy and sleep hygiene for insomnia and nightmares

    Behavioral: Written Exposure Therapy (WET) · Behavioral: Sleep Hygiene

  • Experimental
    Written exposure therapy and CBT for insomnia and nightmares

    Behavioral: Cognitive-Behavioral Therapy for Insomnia (CBTi) · Behavioral: Cognitive Behavioral Therapy for Nightmares (CBTn) · Behavioral: Written Exposure Therapy (WET)

Interventions

  • BehavioralCognitive-Behavioral Therapy for Insomnia (CBTi)

    CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.

  • BehavioralCognitive Behavioral Therapy for Nightmares (CBTn)

    CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.

  • BehavioralWritten Exposure Therapy (WET)

    WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.

  • BehavioralSleep Hygiene

    Involves reviewing sleep diary data, sleep education, and reviewing and discussing sleep hygiene practices.

05

What researchers measure

Primary outcomes

  1. Posttraumatic Stress Disorder Checklist (PCL-5)

    Self-report measure update of the PCL designed to assess PTSD symptoms as defined by the DSM-5. Total scores range from 0-80 (higher scores indicate greater PTSD severity).

    Time frame: Change from baseline through 3 and 6 month follow-up assessment

  2. Insomnia Severity Index (ISI)

    The ISI assesses perceived severity of insomnia. Total scores range from 0-28 (higher scores indicate greater insomnia severity).

    Time frame: Change from baseline through 3 and 6 month follow up

  3. Nightmare Disorders Index

    The NDI is a self-report assessment of nightmare disorder.

    Time frame: Change from baseline through 3 and 6 month assessments

Secondary outcomes

  1. Clinician Administered PTSD Scale (CAPS-5)

    The CAPS-5 is a structured clinical interview that assesses the presence and severity of PTSD symptoms. Total scores range from 0-80 (higher scores indicate greater PTSD severity).

    Time frame: Change from baseline to 1-month follow-up assessment

  2. Structured Clinical Interview for DSM-5 Sleep Disorders- Revised (SCISD-R)

    The SCISD-R is a semi-structured interview designed to obtain a sleep history and screen for certain sleep disorders and diagnose others, including insomnia, hypersomnia, circadian rhythm sleep-wake disorders, sleep-disordered breathing, and parasomnias.

    Time frame: Change from baseline to 1-month follow-up assessment

  3. Generalized Anxiety Disorder Screener (GAD-7)

    GAD-7 is a 7-item measure that assesses generalized anxiety symptomology. Total scores range from 0-21 (higher scores indicate greater anxiety).

    Time frame: Change from baseline through 3 and 6 month follow-up assessment

  4. Trauma-Related Nightmare Survey (TRNS)

    The TRNS assesses nightmare frequency, disturbance, and characteristics

    Time frame: Change from baseline through 3 and 6 month follow-up assessment

  5. Depressive Symptoms Index-Suicidality Subscale (DSI-SS)

    The DSI-SS is a self-report measure of suicidal ideation, plans, perceived control over ideation, and impulses for suicide. Total scores range from 0-12 (higher scores indicate greater suicidality).

    Time frame: Change from baseline through 3 and 6 month follow up assessment

  6. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 assess the severity of affective and somatic symptoms related to depression; items correspond to the diagnostic criteria for major depression disorder. Total scores range from 0-27 (higher scores indicate greater depressive symptom severity).

    Time frame: Change from baseline through 3 and 6 follow-up assessment

  7. Brief Inventory of Psychosocial Functioning (B-IPF)

    B-IPF is a 7-item measure of functioning in seven life domains: romantic relationship, relationship with children, family relationships, friendships and socializing, work, training and education, and activities of daily living. Total scores range from 0-42 (higher scores indicate greater functional impairment).

    Time frame: Change from baseline through 3 and 6 month follow up

Other outcomes

  1. Neuropsychological battery

    The Neuropsychological battery draws from the from NIH toolbox Cognitive Battery and is comprised of the following tasks: Picture Vocab, Face Name Associative Memory Exam Test, Flanker Task, Oral Symbol Digit, Picture Sequence, Pattern Comparison, Dimensional Change, and Face Name Associative Memory Exam Delay.

    Time frame: Change from second baseline to 1-month follow-up assessment

  2. Split Week Self-Assessment of Sleep Survey (SASS-Y)

    The SASS-Y measures average bedtime, sleep time, sleep onset latency, number of awakenings, wake time after sleep onset, wake time, out of bedtime and sleep quality.

    Time frame: Change from baseline through 3 and 6 month follow up assessments

  3. Sleep Diary and Nightmare Log

    The Sleep Diary and Nightmare Log assess daily subjective sleep patterns and to inform treatment recommendations.

    Time frame: Change from second baseline through to the end of treatment

  4. History of Head Injuries

    History of Head Injuries is a 3 question screener that assesses for head injury and altered consciousness.

    Time frame: Measured during baseline

  5. Health Questionnaire

    Health Questionnaire measures medical and mental health diagnoses that respondents have received, medical board and disability status, medications taken, and caffeine use

    Time frame: Measured at baseline

  6. Fitbit Inspire HR data will be downloaded through the Fitabase platform

    Fitbit Inspire HR will measure heart rate, physical activity, and nighttime wakefulness.

    Time frame: Change from second baseline through 3 and 6 month follow-up

  7. Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

    Q-SF is a 16-item measure of life satisfaction and enjoyment in different areas of life over the past week. Total scores range from 14-70 (higher scores indicate greater enjoyment and satisfaction with life).

    Time frame: Change from baseline through 3 and 6 month follow up assessments

  8. Credibility and Expectancy Questionnaire (CEQ)

    The CEQ is a 6-item measure that was designed to assess treatment expectancy and rationale credibility for use in clinical outcomes studies

    Time frame: Change from pre-workshop through 1 month follow up

06

Study locations

1 of 1 sites recruiting
  • Fort Hood
    Kileen, Texas 76544, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — The data used to conduct these analyses are stored in the STRONG STAR Repository. Deidentified data can be accessed by emailing repository@strongstar.org

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07069517
Lead sponsor
Palo Alto Veterans Institute for Research
Collaborators
The University of Texas Health Science Center at San Antonio, University of Arizona, NDRI-USA, Inc.
Responsible party
Carmen McLean (Clinical Psychologist, Palo Alto Veterans Institute for Research) — Principal investigator
First posted
Jul 16, 2025
Start date
Dec 2, 2025 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Dec 3, 2025

Study contacts

Carmen McLean, PhD
Contact
carmen.mclean4@va.gov
650-614-9997

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion